Koji Matsuo1, Hiroko Machida2, Shinya Matsuzaki3, Brendan H Grubbs4, Maximilian Klar5, Lynda D Roman6, Anil K Sood7, David M Gershenson7, Jason D Wright8. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu. 2. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. 4. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. 5. Department of Obstetrics and Gynecology, University of Freiburg, Freiburg, Germany. 6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 7. Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD-Anderson Cancer Center, Houston, TX, USA. 8. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Abstract
OBJECTIVE: To describe how population-based statistics for rare epithelial ovarian cancers are evolving. METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2016. Overall survival (OS) of clear cell (OCCC), mucinous (MOC), and low-grade serous (LGSOC) ovarian cancers were compared to high-grade serous ovarian cancer (HGSOC) by fitting a propensity score matching. RESULTS: Among 113,365 ovarian malignancies, 5780 OCCCs (5.1%), 7561 MOCs (6.7%), and 2021 LGSOCs (1.8%) were compared to 38,199 HGSOCs. OCCCs and MOCs were more likely to be diagnosed with stage I disease compared to HGSOC (57.0-59.5% versus 8.6%, P<0.001). For early-stage disease, OCCC (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.82-1.01) and MOC (HR 0.94, 95%CI 0.85-1.04) had similar OS to HGSOC whereas LGSOC had superior OS (HR 0.93, 95%CI 0.89-0.97) versus HGSOC. Conversely, for advanced-stage disease, OCCC (HR 1.42, 95%CI 1.32-1.53) and MOC (HR 1.11, 95%CI 1.09-1.13) had poorer OS whereas LGSOC (HR 0.86, 95%CI 0.84-0.89) had superior OS compared to HGSOC. OCCC (HR range, 1.92-2.45) and MOC (HR range, 1.73-2.22) had particularly poorer OS in the first three years following diagnosis compared to HGSOC. Population-level statistics for advanced-stage disease showed that 5-year OS rates have increased in HGSOC (16.9% to 36.8%, P<0.001) and LGSOC (50.8% to 66.4%, P=0.010); but remain unchanged for OCCC (21.0% to 28.2%, P=0.174) and MOC (21.4% to 16.5%, P=0.102). CONCLUSION: OCCC, MOC, and LGSOC comprise 2-7% of ovarian malignancies, have distinct characteristics and survival compared to HGSOC. While these rare tumors have a favorable to comparable prognosis in early-stage disease, disproportionally poor survival in advanced-stage OCCC and MOC highlights the need for further research into novel treatment strategies.
OBJECTIVE: To describe how population-based statistics for rare epithelial ovarian cancers are evolving. METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2016. Overall survival (OS) of clear cell (OCCC), mucinous (MOC), and low-grade serous (LGSOC) ovarian cancers were compared to high-grade serous ovarian cancer (HGSOC) by fitting a propensity score matching. RESULTS: Among 113,365 ovarian malignancies, 5780 OCCCs (5.1%), 7561 MOCs (6.7%), and 2021 LGSOCs (1.8%) were compared to 38,199 HGSOCs. OCCCs and MOCs were more likely to be diagnosed with stage I disease compared to HGSOC (57.0-59.5% versus 8.6%, P<0.001). For early-stage disease, OCCC (hazard ratio [HR] 0.91, 95% confidence interval [CI] 0.82-1.01) and MOC (HR 0.94, 95%CI 0.85-1.04) had similar OS to HGSOC whereas LGSOC had superior OS (HR 0.93, 95%CI 0.89-0.97) versus HGSOC. Conversely, for advanced-stage disease, OCCC (HR 1.42, 95%CI 1.32-1.53) and MOC (HR 1.11, 95%CI 1.09-1.13) had poorer OS whereas LGSOC (HR 0.86, 95%CI 0.84-0.89) had superior OS compared to HGSOC. OCCC (HR range, 1.92-2.45) and MOC (HR range, 1.73-2.22) had particularly poorer OS in the first three years following diagnosis compared to HGSOC. Population-level statistics for advanced-stage disease showed that 5-year OS rates have increased in HGSOC (16.9% to 36.8%, P<0.001) and LGSOC (50.8% to 66.4%, P=0.010); but remain unchanged for OCCC (21.0% to 28.2%, P=0.174) and MOC (21.4% to 16.5%, P=0.102). CONCLUSION: OCCC, MOC, and LGSOC comprise 2-7% of ovarian malignancies, have distinct characteristics and survival compared to HGSOC. While these rare tumors have a favorable to comparable prognosis in early-stage disease, disproportionally poor survival in advanced-stage OCCC and MOC highlights the need for further research into novel treatment strategies.
Authors: Michael Frumovitz; Kathleen M Schmeler; Anais Malpica; Anil K Sood; David M Gershenson Journal: Gynecol Oncol Date: 2010-03-23 Impact factor: 5.482
Authors: Jonathan A Ledermann; Daniela Luvero; Aaron Shafer; Dennis O'Connor; Giorgia Mangili; Michael Friedlander; Jacobus Pfisterer; Mansoor R Mirza; Jae-Weon Kim; Jerome Alexandre; Amit Oza; Jubilee Brown Journal: Int J Gynecol Cancer Date: 2014-11 Impact factor: 3.437
Authors: Maria B Schiavone; Thomas J Herzog; Sharyn N Lewin; Israel Deutsch; Xuming Sun; William M Burke; Jason D Wright Journal: Am J Obstet Gynecol Date: 2011-06-21 Impact factor: 8.661
Authors: Koji Matsuo; Hiroko Machida; Rachel S Mandelbaum; Brendan H Grubbs; Lynda D Roman; Anil K Sood; David M Gershenson Journal: Gynecol Oncol Date: 2019-02-20 Impact factor: 5.482
Authors: Xiaoxin I Yao; Xiaofei Wang; Paul J Speicher; E Shelley Hwang; Perry Cheng; David H Harpole; Mark F Berry; Deborah Schrag; Herbert H Pang Journal: J Natl Cancer Inst Date: 2017-08-01 Impact factor: 13.506
Authors: T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi Journal: Cancer Date: 2000-06-01 Impact factor: 6.860
Authors: Allison Gockley; Konrad Pagacz; Stephen Fiascone; Konrad Stawiski; Nicole Holub; Kathleen Hasselblatt; Daniel W Cramer; Wojciech Fendler; Dipanjan Chowdhury; Kevin M Elias Journal: Front Oncol Date: 2022-04-21 Impact factor: 5.738